Piramal Pharma (NSE:PPLPHARMA) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
52 GF Score
Price ₹171.99
GF Value ₹174.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Piramal Pharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Piramal Pharma's operating assets for the quarter that ended in Mar. 2026 was ₹166,302 Mil. Piramal Pharma's operating liabilities for the quarter that ended in Mar. 2026 was ₹41,278 Mil. Piramal Pharma's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Piramal Pharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Piramal Pharma Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Scaled Net Operating Assets Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial 1.81 0.92 0.83 0.82 0.80

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:PPLPHARMA vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Piramal Pharma Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Scaled Net Operating Assets falls into.


NSE:PPLPHARMA
52GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Piramal Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(166302.1-41278.4)/156775.9
=0.80

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=179650.4 - 13348.3
=166302.1

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=98024.2 - 44354 - 12391.8
=41278.4

Piramal Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(166302.1-41278.4)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=179650.4 - 13348.3
=166302.1

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=98024.2 - 44354 - 12391.8
=41278.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹171.99 is trading 1.3% below its estimated GF Value™ of ₹174.31. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹174.31 vs. price of ₹171.99 (1.3% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
52GF Score

Get the complete analysis for NSE:PPLPHARMA

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹171.99
Price
₹174.31
GF Value